Cyclin-dependent kinase 7

Cyclin-dependent kinase 7

Cyclin-dependent kinase 7 (CDK7) is a crucial enzyme in the regulation of the cell cycle and transcription. It is a member of the cyclin-dependent kinase family, which are serine/threonine kinases that play significant roles in cell cycle control and transcription regulation.

Structure and Function

CDK7 is part of the CDK-activating kinase (CAK) complex, which also includes cyclin H and the accessory protein MAT1. The CAK complex is responsible for activating other CDKs by phosphorylating a threonine residue in their T-loop, a critical step for their activation.

CDK7 is unique among CDKs because it has dual roles:

• Cell Cycle Regulation: CDK7 activates CDKs involved in cell cycle progression, such as CDK1, CDK2, CDK4, and CDK6. This activation is essential for the transition between different phases of the cell cycle.

• Transcription Regulation: CDK7 is also a component of the general transcription factor TFIIH, where it phosphorylates the C-terminal domain (CTD) of RNA polymerase II. This phosphorylation is crucial for the initiation and regulation of transcription.

Role in Cell Cycle

CDK7, through its role in the CAK complex, is pivotal in the regulation of the cell cycle. By activating other CDKs, CDK7 ensures the proper progression through the cell cycle phases:

• G1 Phase: Activation of CDK4 and CDK6, which are important for the G1 to S phase transition.
• S Phase: Activation of CDK2, which is crucial for DNA replication.
• M Phase: Activation of CDK1, which is necessary for mitosis.

Role in Transcription

In the context of transcription, CDK7 is part of the TFIIH complex, which is involved in the initiation of transcription by RNA polymerase II. CDK7 phosphorylates the CTD of RNA polymerase II, facilitating the transition from transcription initiation to elongation.

Clinical Significance

CDK7 has been implicated in various cancers due to its role in cell cycle regulation and transcription. Overexpression or dysregulation of CDK7 can lead to uncontrolled cell proliferation, a hallmark of cancer. As a result, CDK7 is considered a potential target for cancer therapy.

Several CDK7 inhibitors are currently being investigated for their therapeutic potential in cancer treatment. These inhibitors aim to block the kinase activity of CDK7, thereby halting the proliferation of cancer cells.

Research and Development

Ongoing research is focused on understanding the precise mechanisms by which CDK7 regulates the cell cycle and transcription. Additionally, the development of specific CDK7 inhibitors is an active area of pharmaceutical research, with the goal of creating effective cancer treatments.

See Also

• Cyclin-dependent kinase
• Cell cycle
• Transcription (biology)
• TFIIH

References

• Fisher, R. P. (2005). Secrets of a double agent: CDK7 in cell-cycle control and transcription. Journal of Cell Science, 118(22), 5171-5180.
• Larochelle, S., et al. (2007). Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nature Structural & Molecular Biology, 14(7), 697-704.